[go: up one dir, main page]

CO5580742A2 - Metodos y formas de dosificacion para la administracion con- trolada de paliperidona - Google Patents

Metodos y formas de dosificacion para la administracion con- trolada de paliperidona

Info

Publication number
CO5580742A2
CO5580742A2 CO05018509A CO05018509A CO5580742A2 CO 5580742 A2 CO5580742 A2 CO 5580742A2 CO 05018509 A CO05018509 A CO 05018509A CO 05018509 A CO05018509 A CO 05018509A CO 5580742 A2 CO5580742 A2 CO 5580742A2
Authority
CO
Colombia
Prior art keywords
approximately
dosage form
hours
administration
further characterized
Prior art date
Application number
CO05018509A
Other languages
English (en)
Inventor
Noymi V Yam
Iran Reyes
Nipun Davar
Atul D Ayer
Julie Lee
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31191280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5580742(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of CO5580742A2 publication Critical patent/CO5580742A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

1.- Una forma de dosificación para tratar a un sujeto que comprende: una cantidad farmacéuticamente eficaz de paliperidona, risperidona o una sal farmacéuticamente aceptable de la misma, en donde dicha forma de dosificación mantiene un índice de liberación ascendente de paliperidona, risperidona o una sal farmacéuticamente aceptable de la misma a lo largo de un periodo de tiempo prolongado.2.- La forma de dosificación de conformidad con la reivindicación 1, caracterizada además porque el índice de liberación ascendente se mantiene por aproximadamente 10 a aproximadamente 24 horas después de la administración.3.- La forma de dosificación de conformidad con la reivindicación 1, caracterizada además porque el índice de liberación ascendente se mantiene por aproximadamente 16 a aproximadamente 22 horas después de la administración. 4.- La forma de dosificación de conformidad con la reivindicación 1, caracterizada además porque el índice de liberación ascendente se mantiene por aproximadamente 18 a aproximadamente 21 horas después de la administración.5.- La forma de dosificación de conformidad con la reivindicación 1, caracterizada además porque la Cmax se alcanza a aproximadamente 14 horas después la administración.6.- La forma de dosificación de conformidad con la reivindicación 1, caracterizada además porque la Cmax se alcanza a aproximadamente 16 horas a aproximadamente 22 horas después de la administración.7.- La forma de dosificación de conformidad con la reivindicación 1, caracterizada además porque la Cmax se alcanza a aproximadamente 18 horas a aproximadamente 21 horas después de la administración.8.- La forma de dosificación de conformidad con la reivindicación 1, caracterizada además porque la Cmax se alcanza a aproximadamente 18 horas a aproximadamente 22 horas después de la administración.9.- La forma de dosificación de conformidad con la reivindicación 1, caracterizada además porque la forma de dosificación es adecuada para administrarse una vez al día.
CO05018509A 2002-07-29 2005-02-28 Metodos y formas de dosificacion para la administracion con- trolada de paliperidona CO5580742A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39959002P 2002-07-29 2002-07-29
US40600502P 2002-08-26 2002-08-26

Publications (1)

Publication Number Publication Date
CO5580742A2 true CO5580742A2 (es) 2005-11-30

Family

ID=31191280

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05018509A CO5580742A2 (es) 2002-07-29 2005-02-28 Metodos y formas de dosificacion para la administracion con- trolada de paliperidona

Country Status (28)

Country Link
US (1) US20040092534A1 (es)
EP (1) EP1539115B1 (es)
JP (1) JP4500679B2 (es)
KR (1) KR100699516B1 (es)
CN (1) CN1684670A (es)
AR (1) AR040721A1 (es)
AT (1) ATE373472T1 (es)
AU (1) AU2003256844A1 (es)
BR (1) BR0313139A (es)
CA (1) CA2494234C (es)
CO (1) CO5580742A2 (es)
CY (1) CY1107096T1 (es)
DE (1) DE60316454T2 (es)
DK (1) DK1539115T3 (es)
ES (1) ES2293039T3 (es)
HR (1) HRP20050077B1 (es)
IL (1) IL166489A (es)
MX (1) MXPA05001191A (es)
MY (1) MY137049A (es)
NO (1) NO324821B1 (es)
NZ (1) NZ570198A (es)
PE (1) PE20040132A1 (es)
PL (1) PL210119B1 (es)
PT (1) PT1539115E (es)
RU (1) RU2321391C2 (es)
TW (1) TWI363637B (es)
WO (1) WO2004010981A1 (es)
ZA (1) ZA200501641B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
EP1802286B1 (en) * 2004-08-04 2008-07-23 ALZA Corporation Sustained drug release composition demonstrating an ascending zero order release pattern, methods of manufacturing such a composition
WO2006085856A1 (en) * 2005-02-04 2006-08-17 Alza Corporation Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20060189635A1 (en) * 2005-02-04 2006-08-24 Michelle Kramer Enhanced efficacy benzisoxazole derivative dosage forms and methods
US20070031496A1 (en) * 2005-08-04 2007-02-08 Edgren David E Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties
US20070166381A1 (en) * 2006-01-06 2007-07-19 Iran Reyes Osmotic dosage form with controlled release and fast release aspects
EP1993559B1 (en) 2006-02-03 2016-06-22 OPKO Renal, LLC Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
US20070232624A1 (en) 2006-04-03 2007-10-04 Palumbo Joseph M Use of paliperidone for the treatment of sleep disturbances and/or excessive daytime sleepiness in psychiatric patients
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
US8524749B2 (en) * 2007-02-09 2013-09-03 Alza Corporation Controlled release compositions of tizanidine
JP2010525080A (ja) * 2007-04-25 2010-07-22 プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法
HRP20231142T3 (hr) 2007-04-25 2024-01-05 Eirgen Pharma Ltd. Kontrolirano oslobađanje 25-hidroksivitamina d
CA2683628C (en) 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
PL2079446T3 (pl) * 2007-08-21 2012-04-30 Teva Pharma Preparat paliperidonu o przedłużonym uwalnianiu
US20090087489A1 (en) 2007-09-25 2009-04-02 Bella Gerber Imatinib compositions
SI2234617T2 (sl) 2007-12-19 2025-05-30 Janssen Pharmaceutica Nv Režim odmerjanja v zvezi z dolgodelujočimi paliperidonijevimi estri za injiciranje
US20090247553A1 (en) * 2008-03-27 2009-10-01 Actavis Group Ptc Ehf Highly Pure Paliperidone or a Pharmaceutically Acceptable Salt Thereof Substantially Free of Keto Impurity
WO2010009900A1 (en) * 2008-07-25 2010-01-28 Krka, D.D. Novo Mesto Paliperidone composition comprising solid matrix particles
EP2161019A1 (en) 2008-09-05 2010-03-10 KRKA, D.D., Novo Mesto Prolonged release multiparticulate pharmaceutical composition comprising paliperidone
US20110177137A1 (en) 2008-09-15 2011-07-21 Intas Pharmaceuticals Limited Novel dosage form of paliperidone and process for preparing the same
JP2012504146A (ja) * 2008-09-30 2012-02-16 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド． リスペリドン送達用埋め込み可能型装置およびその使用方法
WO2011018246A2 (en) 2009-08-13 2011-02-17 Synthon B.V. Controlled release paliperidone composition
US20110052687A1 (en) * 2009-08-26 2011-03-03 Glenmark Generics Ltd Extended release pharmaceutical composition of paliperidone
CA2777856A1 (en) * 2009-10-16 2011-04-21 Ranbaxy Laboratories Limited Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
US9271939B2 (en) 2010-03-15 2016-03-01 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
WO2011123476A1 (en) 2010-03-29 2011-10-06 Cytochroma Inc. Methods and compositions for reducing parathyroid levels
CN103209704B (zh) 2010-04-22 2017-10-27 细胞内治疗公司 有机化合物
WO2012014052A2 (en) 2010-07-30 2012-02-02 Micro Labs Limited Novel coated extended release pharmaceutical compositions containing paliperidone
CN102058517A (zh) * 2010-12-31 2011-05-18 泰州万全医药科技有限公司 一种帕潘立酮缓释剂及其制备方法
US20130034605A1 (en) 2011-08-01 2013-02-07 Micro Labs Limited Extended release pharmaceutical compositions containing paliperidone
CN102274164B (zh) * 2011-08-22 2014-07-02 长春健欣生物医药科技开发有限公司 帕潘立酮及帕潘立酮衍生物的注射用缓释凝胶剂
AU2013245702A1 (en) 2012-04-14 2014-11-13 Intra-Cellular Therapies, Inc. Organic compounds
WO2014102741A2 (en) * 2012-12-28 2014-07-03 University Of The Witwatersrand, Johannesburg Pharmaceutical dosage form
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
WO2014145192A1 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
CN103271889B (zh) * 2013-05-23 2015-10-28 沈阳药科大学 帕利哌酮新型递增释放渗透泵制剂及其制备方法
CN103385857A (zh) * 2013-06-29 2013-11-13 北京万全德众医药生物技术有限公司 帕利哌酮的药物组合物
WO2015001488A1 (en) 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Extended-release tablets of paliperidone and processes of preparation thereof
WO2015085004A1 (en) 2013-12-03 2015-06-11 Intra-Cellular Therapies, Inc. Novel methods
CA2944755A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
KR20170012210A (ko) 2014-04-04 2017-02-02 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
US20160000654A1 (en) * 2014-07-07 2016-01-07 Cadila Healthcare Limited Method for determining formulation orientation of asymmetric multi-layered osmotic tablets
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CN104257622B (zh) * 2014-10-01 2020-02-07 浙江华海药业股份有限公司 一种帕利哌酮控释片及其制备方法
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
GR1008842B (el) 2015-08-06 2016-09-05 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσιμο παραγοντα και μεθοδος για την παρασκευη αυτου
CN105147629B (zh) * 2015-09-24 2017-08-25 吉林大学 一种异丁利酮片剂及制备方法
PL3838274T3 (pl) 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
DK3407889T3 (da) 2016-03-25 2021-08-09 Intra Cellular Therapies Inc Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet
CN108883120A (zh) 2016-03-28 2018-11-23 欧普科爱尔兰环球控股有限公司 维生素d治疗方法
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
US20190105277A1 (en) 2016-04-05 2019-04-11 Pharmathen S.A. Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
US20190321367A1 (en) * 2016-11-23 2019-10-24 Children's Hospital Medical Center Paliperidone for treatment of drug refractory irritability and autism spectrum disorder
CN106727392A (zh) * 2016-12-15 2017-05-31 上海奕利制药有限公司 一种帕利哌酮缓释片剂及其制备方法
WO2018126143A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018175969A1 (en) 2017-03-24 2018-09-27 Intra-Cellular Therapies, Inc. Novel compositions and methods
CA3071137A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Prodrugs of substituted heterocycle fused gamma-carbolines
CN111093665A (zh) 2017-07-26 2020-05-01 细胞内治疗公司 有机化合物
WO2019183341A1 (en) 2018-03-23 2019-09-26 Intra-Cellular Therapies, Inc. Organic compounds
CN112088004A (zh) 2018-03-23 2020-12-15 细胞内治疗公司 有机化合物
WO2019237037A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
AU2019331490B2 (en) 2018-08-31 2025-04-24 Intra-Cellular Therapies, Inc. Novel methods
JP7546546B2 (ja) 2018-08-31 2024-09-06 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
EP4134101A1 (en) 2019-07-07 2023-02-15 Intra-Cellular Therapies, Inc. Deuterated lumateperone for the treatment of the bipolar ii disorder
KR102285510B1 (ko) 2019-10-29 2021-08-04 강동국 양액 농도조절용 캡슐 및 그 용도
WO2022231930A1 (en) 2021-04-26 2022-11-03 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
CN113616610B (zh) * 2021-07-30 2023-05-12 石药集团欧意药业有限公司 一种帕利哌酮缓释片及其制备方法
US20230364009A1 (en) * 2022-05-12 2023-11-16 Celanese Eva Performance Polymers Llc Implantable Medical Device for the Delivery of an Antipsychotic
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
EP4642458A1 (en) 2022-12-30 2025-11-05 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656092A (en) * 1985-10-15 1987-04-07 R. P. Scherer Corporation Target shooting capsules
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
PT1033128E (pt) * 1993-09-28 2008-08-08 Scherer Gmbh R P Fabrico de cápsulas de gelatina mole
HU219487B (hu) * 1993-11-19 2001-04-28 Janssen Pharmaceutica Nv. Riszperidont tartalmazó mikrorészecskék, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények és előállításuk
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
WO1998006380A2 (en) * 1996-08-16 1998-02-19 Alza Corporation Dosage form for providing ascending dose of drug
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
JP2002516848A (ja) * 1998-06-03 2002-06-11 アルザ・コーポレーション 長時間の薬物療法を与える方法および装置
US6706282B1 (en) * 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
JP4711510B2 (ja) * 1998-11-02 2011-06-29 アルザ・コーポレーション 抗鬱剤の制御送達
CN1161101C (zh) * 1998-12-17 2004-08-11 阿尔扎有限公司 用多层包衣将填充液体的明胶胶囊转变成控制释放的系统
BR0009437A (pt) * 1999-03-31 2002-01-15 Janssen Pharmaceutica Nv Amido pré-gelatinizado em uma formulação de liberação controlada
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6375981B1 (en) * 2000-06-01 2002-04-23 A. E. Staley Manufacturing Co. Modified starch as a replacement for gelatin in soft gel films and capsules
US6530962B1 (en) * 2001-08-31 2003-03-11 R.P. Scherer Technologies, Inc. Emulsion of water soluble dyes in a lipophilic carrier

Also Published As

Publication number Publication date
ATE373472T1 (de) 2007-10-15
NO324821B1 (no) 2007-12-10
AU2003256844A1 (en) 2004-02-16
US20040092534A1 (en) 2004-05-13
HRP20050077A2 (en) 2005-12-31
DK1539115T3 (da) 2008-01-28
HK1072559A1 (en) 2005-09-02
MXPA05001191A (es) 2005-09-12
DE60316454T2 (de) 2008-06-26
RU2321391C2 (ru) 2008-04-10
TW200418524A (en) 2004-10-01
PT1539115E (pt) 2008-01-14
EP1539115B1 (en) 2007-09-19
NZ570198A (en) 2010-01-29
IL166489A0 (en) 2006-01-15
PL210119B1 (pl) 2011-12-30
NO20050956L (no) 2005-04-27
CA2494234C (en) 2009-10-27
RU2005102105A (ru) 2005-08-10
PE20040132A1 (es) 2004-03-06
JP4500679B2 (ja) 2010-07-14
HRP20050077B1 (hr) 2013-11-22
IL166489A (en) 2014-01-30
PL376258A1 (en) 2005-12-27
CY1107096T1 (el) 2012-10-24
CA2494234A1 (en) 2004-02-05
TWI363637B (en) 2012-05-11
KR100699516B1 (ko) 2007-03-26
EP1539115A1 (en) 2005-06-15
KR20050044895A (ko) 2005-05-13
ES2293039T3 (es) 2008-03-16
CN1684670A (zh) 2005-10-19
JP2005535682A (ja) 2005-11-24
WO2004010981A1 (en) 2004-02-05
BR0313139A (pt) 2005-07-05
AR040721A1 (es) 2005-04-20
ZA200501641B (en) 2005-08-31
DE60316454D1 (de) 2007-10-31
MY137049A (en) 2008-12-31

Similar Documents

Publication Publication Date Title
CO5580742A2 (es) Metodos y formas de dosificacion para la administracion con- trolada de paliperidona
AR048431A1 (es) Formulaciones galenicas de compuestos organicos
NO20074628L (no) Formuleringer av octreotid med kontrollert frigjoring
ES2072397T3 (es) Metodo y dispositivo para la administracion transdermica de dexmedetomidina.
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
AR045972A1 (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas
AR038527A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
IT1276689B1 (it) Forma farmaceutica solida ad uso orale
PE20230735A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
IL319248A (en) Methods for treating depression using orexin-2 receptor antagonists
CL2008000750A1 (es) Metodo para la administracion de una dosis semanal de 2-[6-(3-amino-piperidin-1-il)3-metil-2,4 dioxo-3,4 dihidro-2h-pirimidin-1-il metil]-4 fluoro-benzonitrilo; composicion farmaceutica de una forma de dosificacion individual de dicho compuesto; y su
DK1225881T3 (da) Anvendelsen af dapoxetin, en hurtigt-virkende selektiv serotonin genoptagelseshæmmer, til behandling af seksuel dysfunktion
EP4520398A3 (en) Treatment of prostate cancer
ES2168241T1 (es) Preparacion farmaceutica que contiene tolperisona para administrar por via oral.
DE602006020070D1 (de) Verringerung von schwindel, einer nebenwirkung im zusammenhang mit einer pirfenidon-therapie
PE20010623A1 (es) Uso de (+)-tramadol y/o o-demetiltramadol para tratamiento de urgencia urinaria incrementada y/o incontinencia urinaria
NO20101070L (no) Fremgangsmate til dosering av et medikament, samt doseringsform
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
ATE347358T1 (de) Schwimmende orale formulierungen mit kontrollierter freisetzung von betain
AR027240A1 (es) Combinacion de mirtazapina y gepirona para el tratamiento de la depresion y trastornos relacionados
IS4847A (is) Aðferð til meðferðar gegn hjartabilun þar sem notuð eru mótlyf gegn endóþelíni
ES2099293T3 (es) Compuestos de piridilguanidina para el tratamiento de la disfuncion erectil.
TW200509909A (en) Use of organic compounds
UY28457A1 (es) Nueva composición
WO2005055933A3 (en) Treatment of psoriasis with rosiglitazone

Legal Events

Date Code Title Description
FC Application refused